Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Autor: Linda C. Hemphill, Alberto Yataco, John P. Kane, Qingqing Yang, S.G. Hughes, Sotirios Tsimikas, Joseph L. Witztum, Robert A. Hegele, Manuel Castro-Cabezas, Robert Dufour, Steven Martin, Clinton Corder, Ulrich Julius, Seth J. Baum, Michel Krempf, James Powell, Mark Cervi, Steven Hamstead, Lawrence Galitz, Patrick M. Moriarty, Frank L.J. Visseren, Basil Issa, Traci Turner, Pankaj Vyas, Daniel Gaudet, Eunju Hurh, Erik S.G. Stroes, Peter P. Toth, Christie M. Ballantyne, Bruno Vergès, Cynthia Huffman, Jean Bergeron, Craig Thompson, Richard Shultzaberger, Ioanna Gouni-Berthold, Louis O'Dea, Cecil Murray Farrington, René Valéro, Eric Bruckert, Elisabeth Steinhagen-Thiessen, Abhay Agarwal, Letitia Thompson-Hargrave, Gordon A. Francis, Veronica J. Alexander, Richard Burdick

Publikováno v: The Lancet Diabetes and Endocrinology, 9(5), 264-275. Elsevier BV
The Lancet. Diabetes & Endocrinology
The Lancet. Diabetes & Endocrinology, 2021, 9 (5), pp.264-275. ⟨10.1016/S2213-8587(21)00046-2⟩

Background: Volanesorsen is an antisense oligonucleotide that targets hepatic apolipoprotein C-III synthesis and reduces plasma triglyceride concentration. The aim of this study was to explore the safety and efficacy of volanesorsen in patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f0bbc0c3b73435049e18dbae3f86ae1
https://pure.amc.nl/en/publications/efficacy-and-safety-of-volanesorsen-in-patients-with-multifactorial-chylomicronaemia-compass-a-multicentre-doubleblind-randomised-placebocontrolled-phase-3-trial(2a99109c-0aba-417c-98a2-6f552441ac78).html